ADMA Biologics, Inc.
ADMAADMA BioLogics, Inc. is a biopharmaceutical company specializing in the development and commercialization of immunoglobulin and other plasma-derived therapies. Focused on providing targeted treatments for immune deficiencies and infectious diseases, the company operates manufacturing facilities and has a portfolio aimed at improving patient outcomes through innovative plasma-based biologics.
Company News
Stonepine Capital Management fully exited its position in ANI Pharmaceuticals, selling 38,597 shares worth $2.52 million in Q3. Despite ANI's strong fundamentals—with Q3 revenue surging 54% YoY to $227.8 million and stock up 49% over the past year—the fund's exit appears to be a portfolio rebalancing move toward earlier-stage biotech rather t...
The global plasma derived medicine market is projected to grow from $17.24 billion in 2024 to $37.4 billion by 2034, driven by increasing demand for therapies treating rare and immune disorders, with North America currently dominating the market.
ADMA Biologics will report its second quarter 2025 financial results on August 6, 2025, after market close, with a conference call to discuss financial performance and company updates.
Several mid-cap medical and biotechnology stocks have outperformed the broader market in 2025, including Penumbra Inc, TransMedics Group Inc, and ADMA Biologics Inc. These companies have shown strong momentum, bullish analyst sentiment, and potential for continued upside.
ADMA Biologics, a U.S.-based biopharmaceutical company, has reiterated its strategic advantage through fully domestic manufacturing, commercialization, and supply chain operations. The company's vertically integrated U.S.-based infrastructure ensures supply chain robustness, regulatory compliance, and alignment with federal and private sector pre...
